Theseus Pharmaceuticals is a Boston, MA–based biotechnology company developing pan-variant tyrosine kinase inhibitors designed to anticipate and inhibit new cancer mutations. Its lead candidate, THE-630, is a next-generation pan-variant KIT inhibitor in development for the treatment of refractory GIST. The pipeline also includes a selective EGFR inhibitor intended to overcome C797S-mediated resistance to osimertinib and a third kinase-target program for an undisclosed indication. The company expects to file an IND before the end of the year. Theseus emerged from stealth concurrent with the close of a $100M Series B financing. Leadership includes co-founders William C. Shakespeare, Ph.D. (President of Research and Development) and Iain Dukes, D. Phil. (Interim CEO), and the board now includes representatives from key investors.

Total raised

$100M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2021